

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/10019302/MBW.

Reconsideration of the application in view of the following amendments and remarks is respectfully requested.

### **AMENDMENT**

Please make the following amendments:

In the claims:

Please amend claims 19 and 56 to read as follows:

19. (Twice amended) A method of producing a virus comprising:  
  
introducing into a host cell a recombinant GBV-B viral expression construct comprising a  
  
polynucleotide encoding a 3' terminal sequence of GBV-B, wherein the  
  
polynucleotide comprises 50 contiguous nucleotides from SEQ ID NO:1; and  
  
culturing said host cell under conditions permitting production of a virus from said  
  
construct.
56. (Amended) A method of producing a GBV-B or chimeric GBV-B virus comprising:  
  
obtaining a virus produced by the method of claim 19;  
  
introducing the virus into a second host cell; and  
  
culturing said host cell under conditions permitting production of virus.